<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03694158</url>
  </required_header>
  <id_info>
    <org_study_id>P00029072</org_study_id>
    <secondary_id>U01AI143514</secondary_id>
    <nct_id>NCT03694158</nct_id>
  </id_info>
  <brief_title>Investigating Dupilumab's Effect in Asthma by Genotype</brief_title>
  <acronym>IDEA</acronym>
  <official_title>Effect of IL-4RαR576 Polymorphism on Response to Dupilumab in Asthma, a Genotype-stratified, Randomized, Placebo- Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Boston Children's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Goal of this study is to investigate if individuals ages 12 years and older, carrying the&#xD;
      IL-4RαR576 gene variant, will have a greater response to therapy acting directly on the&#xD;
      anti-IL-4R. This will be conducted by examining the effect of a 48 week therapy with&#xD;
      dupilumab on the rate of asthma exacerbations.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double-blind, randomized, placebo-controlled parallel-group phase 4 clinical trial.&#xD;
&#xD;
      Patients will be genotyped and categorized as those with: 1) the wild type allele&#xD;
      (Q576/Q576), 2) heterozygous allele (Q576/R576), or 3) homozygous mutant allele (R576/R576);&#xD;
      the genotype associated with more severe disease.&#xD;
&#xD;
      After a run-in period of 2-12 weeks to determine asthma control, subjects who fulfill all&#xD;
      inclusion/exclusion criteria will be randomized to receive either subcutaneous Dupilumab or&#xD;
      placebo (1:1 randomization allocation ratio).&#xD;
&#xD;
      This study addresses fundamental mechanisms by which the IL-4Rα-R576 variant drives the&#xD;
      TH2/TH17 disease endotype and the influence of this variant on response to Dupilumab therapy.&#xD;
      It brings together individuals with deep clinical and scientific expertise in allergic&#xD;
      diseases, including epidemiology, genetics, inflammation, and tolerance mechanisms to&#xD;
      investigate, in a coordinated strategy, the hypothesis that the IL-4Rα-R576 variant drives&#xD;
      TH2/TH17 cell inflammation by subverting allergen-specific iTreg cells into TH17 cells.&#xD;
      Asthmatics bearing this endotype will be particularly likely to favorably respond to&#xD;
      Dupilumab therapy by virtue of its prevention of iTreg cell reprogramming into TH17-like&#xD;
      cells, potentially leading to their long-term stability and potential for sustained immune&#xD;
      tolerance.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 8, 2021</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a genotype stratified, double-blind, randomized, placebo-controlled, parallel-group, phase IV clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double blind, placebo controlled.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The rate of asthma exacerbations</measure>
    <time_frame>48 week treatment period</time_frame>
    <description>An exacerbation is an asthma attack for which a clinician prescribed a course of systemic steroids, whether or not the patient took the steroids.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in pre-bronchodilator lung function</measure>
    <time_frame>average of week 4,12, 24,36 and 48 week</time_frame>
    <description>the change in pre-bronchodilator FEV1% predicted from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CASI score</measure>
    <time_frame>average of 4,12, 24, 36, and 48 week</time_frame>
    <description>The change in CASI score from baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dupilumab (Dupixent®) administered subcutaneously every two weeks. An initial dose of 600 mg (two 300 mg injections) followed by 300 mg given every other week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (preparation, administration, packaging, and labeling all equivalent to the treatment) administered subcutaneously every two weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dupilumab</intervention_name>
    <description>anti-IL4 receptor antagonist</description>
    <arm_group_label>Treatment group</arm_group_label>
    <other_name>Dupixent®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for Dupilumab (packaged/administered the same as the active drug)</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Ages 12 years and older&#xD;
&#xD;
          2. Ability to provide informed consent&#xD;
&#xD;
          3. Ability to perform pulmonary function tests&#xD;
&#xD;
          4. Female participants of childbearing potential must have a negative urine pregnancy&#xD;
             test upon study entry&#xD;
&#xD;
          5. Female participants with reproductive potential must agree to use FDA-approved methods&#xD;
             of birth control for the duration of the study2&#xD;
&#xD;
          6. Participant-reported physician or licensed medical practitioner diagnosis of asthma&#xD;
&#xD;
          7. Treatment with medium to high dose ICS (400 mcg to maximum of 2000 mcg per day of&#xD;
             fluticasone propionate or equivalent) for at least 3 months with a stable dose ≥1&#xD;
             month prior to screening OR used a biologic medication for asthma within the past 8&#xD;
             weeks&#xD;
&#xD;
          8. History of asthma exacerbation in the past year&#xD;
&#xD;
        An exacerbation is an asthma attack for which a clinician prescribed a course of systemic&#xD;
        (oral, IV, IM) steroids whether or not the patient took the steroids OR An increase of &gt;50%&#xD;
        of baseline inhaled corticosteroid dose for ≥3 days OR An unscheduled visit for acute&#xD;
        asthma attack (licensed medical practitioner/nurse office, urgent care intervention,&#xD;
        emergency department, or hospitalization)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Chronic lung disease other than asthma, which may impair lung function&#xD;
&#xD;
          2. Current smoker or cessation of smoking ≤6 months prior to Visit 0 screening&#xD;
&#xD;
          3. Current use of any electronic (e) &quot;vaping&quot; device (e.g., e-cigarette, e-cig, mod, vape&#xD;
             pen, JUUL, e-cigar, e-hookah, e-pipe, vape pods) or cessation ≤ 6 months prior to&#xD;
             screening&#xD;
&#xD;
          4. Pregnant or breast feeding&#xD;
&#xD;
          5. Any other condition or abnormality that, in the opinion of the Principal Investigator,&#xD;
             would compromise the safety of the patient or quality of data&#xD;
&#xD;
          6. Evidence that the participant or family may be unreliable or poorly adherent to their&#xD;
             asthma treatment or study procedures&#xD;
&#xD;
          7. Planning to relocate away from the clinical center area before study completion&#xD;
&#xD;
          8. Currently participating in an investigational drug trial or participated in one within&#xD;
             30 days before screening&#xD;
&#xD;
          9. Currently being treated with immunosuppressive/immunomodulatory or other&#xD;
             investigational agents or biologics for conditions other than asthma, or used a&#xD;
             biologic for a non-asthma indication within the past 6 months&#xD;
&#xD;
         10. History of respiratory illness requiring antibiotics or systemic corticosteroids,&#xD;
             including asthma exacerbations, within the past 4 weeks (evaluated at time of&#xD;
             screening visit)&#xD;
&#xD;
         11. History of alcohol or illicit substance abuse within 6 months of screening&#xD;
&#xD;
         12. Neutropenia (&lt;1,000/mm3) or thrombocytopenia (&lt;100,000/mm3) or hemoglobin &lt; 100 g/L&#xD;
             (10 g/dL) or blood eosinophils &gt; 1500/mm3 at screening&#xD;
&#xD;
         13. Administration of a live vaccine within 4 weeks of screening&#xD;
&#xD;
         14. Currently receiving allergen immunotherapy (food or aeroallergen) other than an&#xD;
             established maintenance regimen implemented continuously for a minimum of 2 months.&#xD;
             Individuals receiving aeroallergen immunotherapy must be willing to stay on it for the&#xD;
             duration of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wanda Phipatanakul</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston Children's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wanda Phipatanakul, MD, MS</last_name>
    <phone>857-218-5336</phone>
    <email>Wanda.Phipatanakul@childrens.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amparito Cunningham</last_name>
    <email>asthma@childrens.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amparito Cunningham, MD. MPH.</last_name>
      <phone>857-218-5531</phone>
      <email>Amparito.Cunningham@childrens.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Conor Brockway</last_name>
      <phone>857-218-3819</phone>
      <email>conor.brockway@childrens.harvard.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Wanda Phipatanakul, MD.MS.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angeles Cinelli</last_name>
      <email>mcinelli@bwh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Eliot Israel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sherae Hereford, RN</last_name>
      <phone>313-207-2453</phone>
      <email>sherefo3@hfhs.org</email>
    </contact>
    <investigator>
      <last_name>Haejin Kim, MD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Atlantic Health System</name>
      <address>
        <city>Cedar Knolls</city>
        <state>New Jersey</state>
        <zip>07927</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beverly Obipso</last_name>
      <phone>908-934-0555</phone>
      <phone_ext>78625</phone_ext>
      <email>Beverly.Obispo@atlantichealth.org</email>
    </contact>
    <investigator>
      <last_name>John Oppenheimer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Lai PS, Massoud AH, Xia M, Petty CR, Cunningham A, Chatila TA, Phipatanakul W. Gene-environment interaction between an IL4R variant and school endotoxin exposure contributes to asthma symptoms in inner-city children. J Allergy Clin Immunol. 2018 Feb;141(2):794-796.e3. doi: 10.1016/j.jaci.2017.08.023. Epub 2017 Sep 21.</citation>
    <PMID>28943468</PMID>
  </reference>
  <reference>
    <citation>Massoud AH, Charbonnier LM, Lopez D, Pellegrini M, Phipatanakul W, Chatila TA. An asthma-associated IL4R variant exacerbates airway inflammation by promoting conversion of regulatory T cells to TH17-like cells. Nat Med. 2016 Sep;22(9):1013-22. doi: 10.1038/nm.4147. Epub 2016 Aug 1.</citation>
    <PMID>27479084</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 1, 2018</study_first_submitted>
  <study_first_submitted_qc>October 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 3, 2018</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Boston Children's Hospital</investigator_affiliation>
    <investigator_full_name>Wanda Phipatanakul</investigator_full_name>
    <investigator_title>Professor of Pediatrics</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

